Not yet recruitingInterventionalPhase 1Last updated Aug 13, 2026

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-ARC002 Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Overview

ClinicalTrials.gov ID: NCT07763652
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY
Brief Summary: This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-ARC002 Injection in patients with locally advanced or metastatic solid tumors.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 2026Estimated
Primary Completion Date: Dec 2028Estimated
Completion Date: Dec 2028Estimated

Study Record Dates

First Submitted: Aug 10, 2026
First Submitted that Met QC Criteria: Aug 10, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT07591155Recruiting

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06954077Recruiting

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT06718621Recruiting

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05385692Active, not recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

NCT05949619Active, not recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

NCT06475131Recruiting

A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors